Clinical trial NCT03794206: Vesair Balloon Confirmatory Trial (VECTOR)
Official title: CD 1009 Rev A Page 1 of 44 23OCT2018 Vesair Balloon Confirmatory Trial (VECTOR) Use of the Next Generation Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Stress Urinary Incontinence
Lead sponsor: Solace Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2019-01-04
Enrollment: 20
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the subject has provided informed consent and determination that all study entry criteria have been met.


Eligibility criteria: Inclusion Criteria:

* Previously treated with Vesair Balloon within the past 4 years
* Normal voiding function
* Has signed consent
* Willing to undergo cystoscopy
* Available for minimum of 12 months

Exclusion Criteria:

* Last Menstrual Period within past 4 years
* Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
* History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
* Urinary incontinence of neurogenic etiology.
* Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
* Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
* Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
* Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
* History of recurrent (\>1) kidney stones, or one kidney stone within the past 5 years.
* History of an artificial urinary sphincter.
* Presence of gross hematuria and/or blood clots in the urine.
* History of interstitial or follicular cystitis or other painful bladder syndrome.
* Cystocele verified as Stage 3 or higher by PoP-Q Classification.
* Local genital skin infection.
* Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
* Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
* Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
* Non-ambulatory, bedridden or physically unable to complete test exercises.
* History of recent alcoholism or illicit drug abuse within the last year.
* Immunologically suppressed or immunocompromised.
* History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
* Uncontrolled diabetes (persistent A1C levels \>9 percent).
* History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
* Morbid obesity, defined as BMI ≥40.0.
* History of any autoimmune or connective tissue disease or disorder that could impact bladder function

Primary outcomes:
measure: Provocative Pad Weight
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Arlington Heights
country: United States
facility: WomanCare
state: Illinois
city: Shreveport
country: United States
facility: Regional Urology
state: Louisiana
city: Hanover
country: United States
facility: Chesapeake Urology
state: Maryland
city: Owings Mills
country: United States
facility: Chesapeake Urology
state: Maryland
city: Poughkeepsie
country: United States
facility: Premier Medical Group of the Hudson Valley
state: New York
city: Providence
country: United States
facility: Women and Infants dept of Urogynecology
state: Rhode Island
city: Virginia Beach
country: United States
facility: Urology of Virginia
state: Virginia
city: Kirkland
country: United States
facility: Washington Urology
state: Washington
Study officials:
affiliation: Women and Infants Hospital
name: Charles Rardin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: McCammon K, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Rardin C, Kahan R, Green L, Zuckerman J, Rovner E. Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon. Neurourol Urodyn. 2018 Jan;37(1):440-448. doi: 10.1002/nau.23324. Epub 2017 Nov 2.